Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Peripheral blood TCR marker of acute myeloid leukemia and detection kit and application of peripheral blood TCR marker

A technology of acute myeloid cells and markers, applied in the field of genetic engineering, can solve the problem that it cannot be used as a qualitative acute myeloid leukemia detection, and achieve the effects of low cost, high specificity and accuracy, and simple sampling

Pending Publication Date: 2021-07-13
CHENGDU EXAB BIOTECH CO LTD
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

If Auer bodies are found in the cytoplasm, it is more helpful to rule out acute lymphoblastic leukemia (ALL) and make a diagnosis of acute myeloid leukemia. The results of this test can be high or low according to the patient's condition and cannot be used as a qualitative acute myeloid leukemia. Leukemia Detection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peripheral blood TCR marker of acute myeloid leukemia and detection kit and application of peripheral blood TCR marker
  • Peripheral blood TCR marker of acute myeloid leukemia and detection kit and application of peripheral blood TCR marker
  • Peripheral blood TCR marker of acute myeloid leukemia and detection kit and application of peripheral blood TCR marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036]Example 1 Obtaining Acute Myeloid Leukemia TCR Marker CDR3 Sequence Set by Immunogram Analysis

[0037] 1. Sampling and immune map analysis

[0038] Collect 1301 control groups (including healthy people and patients with non-tumor diseases, 1300 people are used for model building, 1 healthy person is used for verification), 41 patients with acute myeloid leukemia (40 people are used for model building, 1 person is used for for verification) and the peripheral blood of a subject with unknown health status (10mL per person), the amino acid sequence of the TCR epitope 3 (CDR3) of the subject and the control group was obtained by high-throughput sequencing, ensuring that each sample The total number of CDR3 sequences of the functional TCR is not less than 25,000;

[0039] 2. Perform random non-replacement sampling on the sequences of samples whose total number of CDR3 sequences of each functional TCR is higher than 30,000, so that the total number of CDR3 sequences of this ...

Embodiment 2

[0045] Example 2 Verification of the specificity of the acute myeloid leukemia TCR marker CDR3 sequence set

[0046] 1. Sampling and immune map analysis

[0047] Peripheral blood (10 mL per person) was collected from 435 tumor patients with non-acute myeloid leukemia and 2 subjects with unknown health status, and the epitope 3 ( CDR3) amino acid sequence, to ensure that the total number of CDR3 sequences of each functional TCR in each sample is not less than 25,000; random non-replacement sampling is performed on the sequences of samples whose total number of CDR3 sequences in each functional TCR is higher than 30,000. The total number of CDR3 sequences of the samples is 30000. So far, the total number of functional TCR CDR3 sequences contained in all samples is 25,000-30,000.

[0048] 2. Randomly select 100 healthy people and 43 non-tumor disease patients from the control group in Example 1.

[0049] 3. According to 100 healthy people, 43 non-neoplastic disease patients, 4...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a peripheral blood TCR marker of acute myeloid leukemia and a detection kit and application of the peripheral blood TCR marker. The marker comprises at least one of proteins of which the sequences are as shown in SEQ ID NO.1-100. On the basis of a high-throughput sequencing method, only a small amount of peripheral blood needs to be adopted, RNA is extracted, an immune map library is established by treating a sample, then through high-throughput sequencing and TCR data analysis, firstly, a characteristic TCR sequence in the peripheral blood of acute myeloid leukemia is determined, then a test result of a to-be-tested sample is compared with the characteristic TCR sequence. Therefore, whether the patient suffers from acute myeloid leukemia is determined. According to the kit, a huge number of acute myeloid leukemia specific TCR sequences can be compared at the same time, and compared with single detection of one or more markers, the kit has higher specificity and accuracy, and the diagnosis efficiency is improved.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering, and in particular relates to a peripheral blood TCR marker of acute myeloid leukemia, a detection kit and application thereof. Background technique [0002] Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem / progenitor cells. It is mainly characterized by abnormal proliferation of primitive and immature myeloid cells in bone marrow and peripheral blood. Acute and severe, the disease progresses rapidly, the natural course of the disease is only a few weeks to several months, the prognosis is dangerous, and it can often be life-threatening if not treated in time. The disease accounts for 30% of childhood leukemia. Children with acute myeloid leukemia are similar to adults (<50 years) in terms of molecular biological changes and response to chemotherapy. Acute myeloid leukemia in infants and young children is more prone to extramedullary leukemia than...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574G01N33/68C07K14/725A61P35/02
CPCG01N33/57426G01N33/57488G01N33/68C07K14/7051A61P35/02G01N2333/7051
Inventor 张志新卓越杨鑫
Owner CHENGDU EXAB BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com